Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Share-based Compensation (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Share-based Compensation for 15 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 4.73% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, up 19.6% year-over-year, with the annual reading at $5.7 million for FY2025, 19.6% up from the prior year.
  • Share-based Compensation hit $1.3 million in Q4 2025 for Cardiff Oncology, down from $1.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.7 million in Q2 2025 to a low of $268000.0 in Q1 2021.
  • Historically, Share-based Compensation has averaged $1.1 million across 5 years, with a median of $1.1 million in 2023.
  • Biggest five-year swings in Share-based Compensation: soared 329.85% in 2022 and later decreased 25.43% in 2024.
  • Year by year, Share-based Compensation stood at $990000.0 in 2021, then grew by 2.22% to $1.0 million in 2022, then decreased by 10.18% to $909000.0 in 2023, then skyrocketed by 32.45% to $1.2 million in 2024, then increased by 4.73% to $1.3 million in 2025.
  • Business Quant data shows Share-based Compensation for CRDF at $1.3 million in Q4 2025, $1.4 million in Q3 2025, and $1.7 million in Q2 2025.